ong-Term Safety Study of KW-6002 (6002-010)
Phase 3
- Conditions
- Parkinson's Disease
- Registration Number
- JPRN-jRCT2080220821
- Lead Sponsor
- Kyowa Hakko Kirin Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
1. Be willing and able to give written informed consent
2. Completion of the study 6002-009
Exclusion Criteria
1. Mini-mental status examination score of 23 or less
2. Less than 70% of compliance in the study 6002-009
3. Emergency deviation in the study 6002-009
4. Pregnant females
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety: adverse events
- Secondary Outcome Measures
Name Time Method Efficacy: 24-hour patient Parkinson's diaries
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie KW-6002's long-term safety in JPRN-jRCT2080220821 for Parkinson's Disease?
How does KW-6002's efficacy compare to standard-of-care MAO-B inhibitors in Phase 3 Parkinson's trials sponsored by Kyowa Hakko Kirin?
Which biomarkers are used to select Parkinson's Disease patients for KW-6002 treatment in JPRN-jRCT2080220821?
What are the potential adverse events and management strategies for KW-6002 in long-term Parkinson's Disease studies?
What related compounds or combination therapies are being explored alongside KW-6002 for Parkinson's Disease by Kyowa Hakko Kirin?